A text message system can monitor postoperative opioid use and shows that many prescribed opioid tablets are unused.
The NIAID will evaluate the vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant, B.1.351.
During the COVID-19 pandemic period, there have been inequities in accessing telemedicine.
Retired doctors and nurses are being called to the front lines of the US COVID-19 vaccination effort.
Patients already receiving opioid use disorder treatment continued to receive care during the early weeks of the COVID-19 pandemic.
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Increased testing has the greatest influence in terms of reducing the average reproduction number of COVID-19.
AstraZeneca has resumed a phase 3 clinical trial investigating AZD1222, its COVID-19 vaccine candidate.
HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.
Guidance is provided for physicians to optimize telemedicine, which can be challenging for older patients.